Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Morphosys GmbH has 4 pending office actions in Biotechnology & Pharmaceuticals. The actions involve 4 distinct examiners and 3 distinct art units, so examiner assignments are fully separate while one art unit handles more than one matter.
MCCOLLUM, ANDREA K is the busiest examiner, with 1 pending matter. The profile shows limited concentration. Counsel can prioritize the individual office actions and use the repeated art-unit assignment to identify common biotechnology prosecution issues without assuming that one examiner's practice governs the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
| LU, CHENG | 1 | 53.8% | +64.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19363223 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | PAK, MICHAEL D | — |
| 18246052 | NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19363223 | ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY | PAK, MICHAEL D | 1674 | §112DP | Final Rejection | — | Pending | Oct 20, 2025 |
| 18246052 | NOVEL HUMAN ANTIBODIES BINDING TO HUMAN CD3 EPSILON | LU, CHENG | 1642 | §112 | Non-Final OA | — | Pending | Mar 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMorphosys GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Michael D Pak has the most, with 1 of Morphosys GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
